EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Distinct Viability, Lubrication, and Proteomic Responses to Clinically Used Hyaluronic Acid Products in Primary Human Fibroblast‐Like Synoviocytes

Tatjana Pejic, Jessica M. Corpuz, Sarah Kerslake, Daniel Young, Antonie Dufour, Holly D. Sparks, Laurie A. Hiemstra, Roman Krawetz

Journal of Orthopaedic Research · 2026-11 · 44 (11)

DOI: 10.1002/jor.70322 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Orthopaedic Research, online erschienen am 18.11.2026. Verfasst von Tatjana Pejic und 7 weiteren Autor:innen. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hyaluronic acid (HA) products are widely used in osteoarthritis (OA) treatment, comparative effects across clinically used products on synovial cell biology and lubrication within the joint remain incompletely characterized. To evaluate the short‐term viability and functional responses of primary human synovium‐derived cells across five clinically used HA products. Primary human fibroblast‐like synoviocytes (FLS) were seeded in multi‐well plates and treated with Cingal, Durolane, Monovisc, NeoVisc, and SportVis at 10%, 25%, and 50% volume/volume (vol/vol) dilutions in culture medium for 72 h. Metabolic viability was assessed using PrestoBlue, and qualitative viability and morphology were evaluated using a live/dead imaging, to assess cellular responses and changes under treatment. Lubrication performance was assessed by rotational tribometry. Liquid chromatography‐tandem mass spectrometry (LC/MS) was performed on synoviocytes treated with Cingal, Monovisc, and an untreated control. All five HA products were generally well‐tolerated by primary human FLS cells. Differences in lubrication performance and proteomic responses, particularly between corticosteroid‐containing and non‐corticosteroid HA formulations, suggest that these products are not biologically interchangeable. These findings warrant further investigation into how product‐specific effects may contribute to variability in clinical response and may help inform patient‐ and disease‐specific treatment approaches.

Zitieren

APA

Pejic, T., Corpuz, J. M., Kerslake, S., Young, D., Dufour, A., Sparks, H. D., Hiemstra, L. A., & Krawetz, R. (2026). Distinct Viability, Lubrication, and Proteomic Responses to Clinically Used Hyaluronic Acid Products in Primary Human Fibroblast‐Like Synoviocytes. Journal of Orthopaedic Research, 44(11). https://doi.org/10.1002/jor.70322

Vancouver

Pejic T, Corpuz JM, Kerslake S, Young D, Dufour A, Sparks HD, et al. Distinct Viability, Lubrication, and Proteomic Responses to Clinically Used Hyaluronic Acid Products in Primary Human Fibroblast‐Like Synoviocytes. Journal of Orthopaedic Research. 2026;44(11). doi:10.1002/jor.70322

BibTeX
@article{Pejic2026,
  author = {Pejic, Tatjana and Corpuz, Jessica M. and Kerslake, Sarah and Young, Daniel and Dufour, Antonie and Sparks, Holly D. and Hiemstra, Laurie A. and Krawetz, Roman},
  title = {Distinct Viability, Lubrication, and Proteomic Responses to Clinically Used Hyaluronic Acid Products in Primary Human Fibroblast‐Like Synoviocytes},
  journal = {Journal of Orthopaedic Research},
  year = {2026},
  volume = {44},
  number = {11},
  doi = {10.1002/jor.70322}
}
Kostenlos starten →